Prostate Cancer Research - Symptoms, Genetics, Screening, Treatment, Information

Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.


Prostate Cancer Research Today

Home

View Latest Issue

Information About Prostate Cancer

Books on Prostate Cancer

Advertising in Research Today

View Other Research Today Publications



Volume 6 (2009), Issue 9 (September)

  1. The Center for Prostate Disease Research (CPDR): a multidisciplinary approach to translational research.
    Urol Oncol, 27(5): 562-9. [Abstract] [Full-text]
  2. Doxazosin-related alpha1-adrenoceptor antagonists with prostate antitumor activity.
    J Med Chem, 52(15): 4951-4. [Abstract] [Full-text]
  3. Isoflavone supplements stimulated the production of serum equol and decreased the serum dihydrotestosterone levels in healthy male volunteers.
    Prostate Cancer Prostatic Dis, 12(3): 247-52. [Abstract] [Full-text]
  4. Measuring therapeutic efficacy in the changing paradigm of castrate-resistant prostate cancer.
    Prostate Cancer Prostatic Dis, 12(3): 241-6. [Abstract] [Full-text]
  5. Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth.
    Prostate, 69(13): 1460-9. [Abstract] [Full-text]
  6. Cell cycle regulator cdk2ap1 inhibits prostate cancer cell growth and modifies androgen-responsive pathway function.
    Prostate, 69(14): 1586-97. [Abstract] [Full-text]
  7. Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy.
    Prostate, 69(14): 1579-85. [Abstract] [Full-text]
  8. Estimation of absolute risk for prostate cancer using genetic markers and family history.
    Prostate, 69(14): 1565-72. [Abstract] [Full-text]
  9. Modeling the effects of obesity and weight gain on PSA velocity.
    Prostate, 69(14): 1573-8. [Abstract] [Full-text]
  10. Common variants in 8q24 are associated with risk for prostate cancer and tumor aggressiveness in men of European ancestry.
    Prostate, 69(14): 1548-56. [Abstract] [Full-text]
  11. Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro.
    Prostate, 69(14): 1529-37. [Abstract] [Full-text]
  12. A novel, spontaneously immortalized, human prostate cancer cell line, Bob, offers a unique model for pre-clinical prostate cancer studies.
    Prostate, 69(14): 1507-20. [Abstract] [Full-text]
  13. Signal transduction responses to lysophosphatidic acid and sphingosine 1-phosphate in human prostate cancer cells.
    Prostate, 69(14): 1493-506. [Abstract] [Full-text]
  14. A [3]ferrocenophane polyphenol showing a remarkable antiproliferative activity on breast and prostate cancer cell lines.
    J Med Chem, 52(15): 4964-7. [Abstract] [Full-text]
  15. Nemo-like kinase induces apoptosis and inhibits androgen receptor signaling in prostate cancer cells.
    Prostate, 69(14): 1481-92. [Abstract] [Full-text]
  16. The alchemy of jargon: Etymologies of urologic neologisms. Number 5: oncology and its vocabulary.
    Prostate, 69(13): 1369-71. [Abstract] [Full-text]
  17. Morphological transition of proliferative inflammatory atrophy to high-grade intraepithelial neoplasia and cancer in human prostate.
    Prostate, 69(13): 1378-86. [Abstract] [Full-text]
  18. Expression of Toll-like receptor 4 in the prostate gland and its association with the severity of prostate cancer.
    Prostate, 69(13): 1387-97. [Abstract] [Full-text]
  19. Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs.
    Prostate, 69(13): 1448-59. [Abstract] [Full-text]
  20. C/EBPbeta regulates metastatic gene expression and confers TNF-alpha resistance to prostate cancer cells.
    Prostate, 69(13): 1435-47. [Abstract] [Full-text]
  21. Targeting of prostate cancer cells by a cytotoxic lentiviral vector containing a prostate stem cell antigen (PSCA) promoter.
    Prostate, 69(13): 1422-34. [Abstract] [Full-text]
  22. Physical activity reduces prostate carcinogenesis in a transgenic model.
    Prostate, 69(13): 1372-7. [Abstract] [Full-text]
  23. The increased expression of periostin during early stages of prostate cancer and advanced stages of cancer stroma.
    Prostate, 69(13): 1398-403. [Abstract] [Full-text]
  24. Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma.
    Mod Pathol, 22(9): 1176-85. [Abstract] [Full-text]
  25. Evidence for field cancerization of the prostate.
    Prostate, 69(13): 1470-9. [Abstract] [Full-text]
  26. Do the risk factors of age, family history of prostate cancer or a higher prostate specific antigen level raise anxiety at prostate biopsy?
    Eur J Cancer, 45(14): 2569-73. [Abstract] [Full-text]
  27. Robotic-assisted laparoscopic and radical retropubic prostatectomy generate similar positive margin rates in low and intermediate risk patients.
    Urol Oncol, 27(5): 529-33. [Abstract] [Full-text]
  28. Tissue-selective RNA interference in prostate cancer cell using prostate specific membrane antigen promoter/enhancer.
    Urol Oncol, 27(5): 539-47. [Abstract] [Full-text]
  29. A single institution experience with biochemical recurrence after radical prostatectomy for tumors that on pathology are of small volume or "insignificant".
    Urol Oncol, 27(5): 509-13. [Abstract] [Full-text]
  30. Prostate carcinoma spatial distribution patterns in Chinese men investigated with systematic transperineal ultrasound guided 11-region biopsy.
    Urol Oncol, 27(5): 520-4. [Abstract] [Full-text]
  31. Prostate tumor alignment and continuous, real-time adaptive radiation therapy using electromagnetic fiducials: clinical and cost-utility analyses.
    Urol Oncol, 27(5): 473-82. [Abstract] [Full-text]
  32. Genetic profile identification in clinically localized prostate carcinoma.
    Urol Oncol, 27(5): 502-8. [Abstract] [Full-text]
  33. A comparative study of seed localization and dose calculation on pre- and post-implantation ultrasound and CT images for low-dose-rate prostate brachytherapy.
    Phys Med Biol, 54(18): 5595-611. [Abstract] [Full-text]
  34. The role of transforming growth factor-beta-mediated tumor-stroma interactions in prostate cancer progression: an integrative approach.
    Cancer Res, 69(17): 7111-20. [Abstract] [Full-text]
  35. Dietary feeding of dibenzoylmethane inhibits prostate cancer in transgenic adenocarcinoma of the mouse prostate model.
    Cancer Res, 69(17): 7096-102. [Abstract] [Full-text]
  36. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.
    Cancer Res, 69(17): 6932-40. [Abstract] [Full-text]
  37. Contrast-enhanced radiotherapy: feasibility and characteristics of the physical absorbed dose distribution for deep-seated tumors.
    Phys Med Biol, 54(18): 5411-25. [Abstract] [Full-text]
  38. Public knowledge of benefits of breast and prostate cancer screening in Europe.
    J Natl Cancer Inst, 101(17): 1216-20. [Abstract] [Full-text]
  39. Microfabricated electrospun collagen membranes for 3-D cancer models and drug screening applications.
    Biomacromolecules, 10(8): 2019-32. [Abstract] [Full-text]
  40. In vivo lactate signal enhancement using binomial spectral-selective pulses in selective MQ coherence (SS-SelMQC) spectroscopy.
    Magn Reson Med, 62(3): 591-8. [Abstract] [Full-text]
  41. Comparing oxygen-sensitive MRI (BOLD R2*) with oxygen electrode measurements: a pilot study in men with prostate cancer.
    Int J Radiat Biol, 85(9): 805-13. [Abstract] [Full-text]
  42. Dynamic MRI and CAD vs. choline MRS: where is the detection level for a lesion characterisation in prostate cancer?
    Int J Radiat Biol, 85(9): 814-24. [Abstract] [Full-text]
  43. A stochastic model for identifying differential gene pair co-expression patterns in prostate cancer progression.
    BMC Genomics, 10: 340. [Abstract] [Full-text]
  44. Dietary glucosinolate intake and risk of prostate cancer in the EPIC-Heidelberg cohort study.
    Int J Cancer, 125(9): 2179-86. [Abstract] [Full-text]
  45. Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells.
    Int J Cancer, 125(9): 2004-13. [Abstract] [Full-text]
  46. A retrospective comparison of anesthetic management of robot-assisted laparoscopic radical prostatectomy versus radical retropubic prostatectomy.
    J Clin Anesth, 21(5): 322-8. [Abstract] [Full-text]
  47. Phytoestrogen modulation of bone-related cytokines and its impact on cell viability in human prostate cancer cells.
    Life Sci, 85(11): 421-30. [Abstract] [Full-text]
  48. miR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer.
    J Biol Chem, 284(37): 24696-704. [Abstract] [Full-text]
  49. Hypoxia and the metabolic phenotype of prostate cancer cells.
    Biochim Biophys Acta, 1787(12): 1433-43. [Abstract] [Full-text]
  50. External radiotherapy for prostate cancer with or without androgen deprivation: Geneva, 1991 to 2004.
    Swiss Med Wkly, 139(35): 511-7. [Abstract] [Full-text]
  51. Image-guided radiotherapy in near real time with intensity-modulated radiotherapy megavoltage treatment beam imaging.
    Int J Radiat Oncol Biol Phys, 75(2): 603-10. [Abstract] [Full-text]
  52. Physiologic reactions after proton beam therapy in patients with prostate cancer: significance of urinary autoactivation.
    Int J Radiat Oncol Biol Phys, 75(2): 580-6. [Abstract] [Full-text]
  53. Combination treatment of hydrogen peroxide and X-rays induces apoptosis in human prostate cancer PC-3 cells.
    Int J Radiat Oncol Biol Phys, 75(2): 449-54. [Abstract] [Full-text]
  54. Lupeol triterpene, a novel diet-based microtubule targeting agent: disrupts survivin/cFLIP activation in prostate cancer cells.
    Biochem Biophys Res Commun, 388(3): 576-82. [Abstract] [Full-text]
  55. Correlation between pre- and postimplant dosimetry for iodine-125 seed implants for localized prostate cancer.
    Int J Radiat Oncol Biol Phys, 75(2): 626-30. [Abstract] [Full-text]
  56. Genistein synergizes with RNA interference inhibiting survivin for inducing DU-145 of prostate cancer cells to apoptosis.
    Cancer Lett, 284(2): 189-97. [Abstract] [Full-text]
  57. Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer.
    Int J Radiat Oncol Biol Phys, 75(2): 413-20. [Abstract] [Full-text]
  58. Prospective study evaluating postoperative radiotherapy plus 2-year androgen suppression for post-radical prostatectomy patients with pathologic T3 disease and/or positive surgical margins.
    Int J Radiat Oncol Biol Phys, 75(2): 407-12. [Abstract] [Full-text]
  59. Prostate cancer: a newly discovered route for testosterone to reach the prostate : Treatment by super-selective intraprostatic androgen deprivation.
    Andrologia, 41(5): 305-15. [Abstract] [Full-text]
  60. Outcomes of locally advanced (T3 or greater) prostate cancer in men undergoing robot-assisted laparoscopic prostatectomy.
    J Endourol, 23(9): 1519-22. [Abstract] [Full-text]
  61. Increased expression of class III beta-tubulin in castration-resistant human prostate cancer.
    Br J Cancer, 101(6): 951-6. [Abstract] [Full-text]
  62. Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: involvement of CB2.
    Br J Cancer, 101(6): 940-50. [Abstract] [Full-text]
  63. Prostate cancer as a first and second cancer: effect of family history.
    Br J Cancer, 101(6): 935-9. [Abstract] [Full-text]
  64. Intraoperative photodynamic evaluation of surgical margins during endoscopic extraperitoneal radical prostatectomy with the use of 5-aminolevulinic acid.
    J Endourol, 23(9): 1387-94. [Abstract] [Full-text]
  65. Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy.
    J Clin Oncol, 27(26): 4306-13. [Abstract] [Full-text]
  66. Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management.
    J Clin Oncol, 27(26): 4321-6. [Abstract] [Full-text]
  67. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era.
    J Clin Oncol, 27(26): 4300-5. [Abstract] [Full-text]
  68. Robot-assisted radical prostatectomy: current evaluation of surgical margins in clinically low-, intermediate-, and high-risk prostate cancer.
    J Endourol, 23(9): 1461-5. [Abstract] [Full-text]
  69. Influence of NCI cancer center attendance on mortality in lung, breast, colorectal, and prostate cancer patients.
    Med Care Res Rev, 66(5): 542-60. [Abstract] [Full-text]
  70. The chemopreventive bioflavonoid apigenin inhibits prostate cancer cell motility through the focal adhesion kinase/Src signaling mechanism.
    Cancer Prev Res (Phila Pa), 2(9): 830-41. [Abstract] [Full-text]
  71. Periprostatic adipose tissue as a modulator of prostate cancer aggressiveness.
    J Urol, 182(4): 1621-7. [Abstract] [Full-text]
  72. Electrical properties of prostatic tissues: I. Single frequency admittivity properties.
    J Urol, 182(4): 1600-7. [Abstract] [Full-text]
  73. Electrical properties of prostatic tissues: II. Spectral admittivity properties.
    J Urol, 182(4): 1608-13. [Abstract] [Full-text]
  74. Semaphorin 3B and 3F single nucleotide polymorphisms are associated with prostate cancer risk and poor prognosis.
    J Urol, 182(4): 1614-20. [Abstract] [Full-text]
  75. Extensive biopsies and transurethral prostate resection in men with previous negative biopsies and high or increasing prostate specific antigen.
    J Urol, 182(4): 1342-9. [Abstract] [Full-text]
  76. Hyaluronic acid and HYAL-1 in prostate biopsy specimens: predictors of biochemical recurrence.
    J Urol, 182(4): 1350-6. [Abstract] [Full-text]
  77. Pathological effects of prostate cancer correlate with neuroendocrine differentiation and PTEN expression after bicalutamide monotherapy.
    J Urol, 182(4): 1378-84. [Abstract] [Full-text]
  78. Tertiary Gleason patterns and biochemical recurrence after prostatectomy: proposal for a modified Gleason scoring system.
    J Urol, 182(4): 1364-70. [Abstract] [Full-text]
  79. Location, extent and number of positive surgical margins do not improve accuracy of predicting prostate cancer recurrence after radical prostatectomy.
    J Urol, 182(4): 1357-63. [Abstract] [Full-text]
  80. Optimizing prostate cancer detection: 8 versus 12-core biopsy protocol.
    J Urol, 182(4): 1329-36. [Abstract] [Full-text]
  81. Image guided photothermal focal therapy for localized prostate cancer: phase I trial.
    J Urol, 182(4): 1371-7. [Abstract] [Full-text]
  82. Prostatic transition zone directed needle biopsies uncommonly sample clinically relevant transition zone tumors.
    J Urol, 182(4): 1337-41. [Abstract] [Full-text]
  83. Cancer incidence among pesticide applicators exposed to butylate in the Agricultural Health Study (AHS).
    Environ Res, 109(7): 860-8. [Abstract] [Full-text]
  84. Generation of an epigenetic signature by chronic hypoxia in prostate cells.
    Hum Mol Genet, 18(19): 3594-604. [Abstract] [Full-text]
  85. Quantitative trait loci predicting circulating sex steroid hormones in men from the NCI-Breast and Prostate Cancer Cohort Consortium (BPC3).
    Hum Mol Genet, 18(19): 3749-57. [Abstract] [Full-text]
  86. Inhibitory mechanisms of Agaricus blazei Murill on the growth of prostate cancer in vitro and in vivo.
    J Nutr Biochem, 20(10): 753-64. [Abstract] [Full-text]
  87. Effect of a prostaglandin--given rectally for prevention of radiation-induced acute proctitis--on late rectal toxicity. Results of a phase III randomized, placebo-controlled, double-blind study.
    Strahlenther Onkol, 185(9): 596-602. [Abstract] [Full-text]
  88. Using cone-beam computed tomography to evaluate the impact of bladder filling status on target position in prostate radiotherapy.
    Strahlenther Onkol, 185(9): 588-95. [Abstract] [Full-text]
  89. Outcomes of localized prostate cancer following conservative management.
    JAMA, 302(11): 1202-9. [Abstract] [Full-text]
  90. Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer.
    Cancer Res, 69(18): 7466-72. [Abstract] [Full-text]
  91. Role of cyclic AMP response element-binding protein in insulin-like growth factor-i receptor up-regulation by sex steroids in prostate cancer cells.
    Cancer Res, 69(18): 7270-7. [Abstract] [Full-text]
  92. Dysfunctional transforming growth factor-beta receptor II accelerates prostate tumorigenesis in the TRAMP mouse model.
    Cancer Res, 69(18): 7366-74. [Abstract] [Full-text]
  93. Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways.
    Cancer Res, 69(18): 7375-84. [Abstract] [Full-text]
  94. miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth.
    Cancer Res, 69(18): 7165-9. [Abstract] [Full-text]
  95. Contemporary risk profile of prostate cancer in the United States.
    J Natl Cancer Inst, 101(18): 1280-3. [Abstract] [Full-text]
  96. The neuroendocrine-derived peptide parathyroid hormone-related protein promotes prostate cancer cell growth by stabilizing the androgen receptor.
    Cancer Res, 69(18): 7402-11. [Abstract] [Full-text]
  97. Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer.
    J Natl Cancer Inst, 101(18): 1272-9. [Abstract] [Full-text]
  98. Case report. Multilocular cystadenoma of the prostate presenting as a giant pelvic mass.
    Br J Radiol, 82(982): e200-1. [Abstract] [Full-text]
  99. The polyamine analog PG11047 potentiates the antitumor activity of cisplatin and bevacizumab in preclinical models of lung and prostate cancer.
    Cancer Chemother Pharmacol, 65(1): 191-5. [Abstract] [Full-text]
  100. Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis.
    Oncogene, 28(37): 3307-19. [Abstract] [Full-text]
  101. Early salvage radiotherapy for patients with PSA relapse after radical prostatectomy.
    J Cancer Res Clin Oncol, 135(11): 1561-7. [Abstract] [Full-text]
  102. Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent.
    Cancer Chemother Pharmacol, 65(1): 177-86. [Abstract] [Full-text]
  103. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
    Expert Rev Anticancer Ther, 9(9): 1211-8. [Abstract] [Full-text]
  104. Towards the definition of prostate cancer-related microRNAs: where are we now?
    Trends Mol Med, 15(9): 381-90. [Abstract] [Full-text]
  105. Characteristics of prostate cancers found in specimens removed by radical cystoprostatectomy for bladder cancer and their relationship with serum prostate-specific antigen level.
    Cancer Sci, 100(10): 1880-4. [Abstract] [Full-text]
  106. Retinoid metabolism and ALDH1A2 (RALDH2) expression are altered in the transgenic adenocarcinoma mouse prostate model.
    Biochem Pharmacol, 78(9): 1127-38. [Abstract] [Full-text]
  107. Association of lower urinary tract symptoms with sexual dysfunction: a cross-cultural study between Japanese and American men with localized prostate cancer.
    BJU Int, 104(8): 1071-6. [Abstract] [Full-text]
  108. The prevalence of erectile dysfunction among Brazilian men screened for prostate cancer.
    BJU Int, 104(8): 1130-3. [Abstract] [Full-text]
  109. Outcomes of patients undergoing radical cystoprostatectomy for bladder cancer with prostatic involvement on final pathology.
    BJU Int, 104(8): 1091-7. [Abstract] [Full-text]
  110. Retrospective analysis of the distance between the neurovascular bundle and prostate cancer foci in radical prostatectomy specimens: its clinical implication in nerve-sparing surgery.
    BJU Int, 104(8): 1085-90. [Abstract] [Full-text]
  111. High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure.
    BJU Int, 104(8): 1058-62. [Abstract] [Full-text]
  112. Five-year longitudinal effect of radical perineal prostatectomy on health-related quality of life in Japanese men, using general and disease-specific measures.
    BJU Int, 104(8): 1077-84. [Abstract] [Full-text]
  113. Intralesional recombinant alpha-interferon for localized prostate cancer: a pilot study with follow-up of >10 years.
    BJU Int, 104(8): 1068-70. [Abstract] [Full-text]
  114. Prospective comparison of five mediators of the systemic response after high-intensity focused ultrasound and targeted cryoablation for localized prostate cancer.
    BJU Int, 104(8): 1063-7. [Abstract] [Full-text]
  115. RapidArc, intensity modulated photon and proton techniques for recurrent prostate cancer in previously irradiated patients: a treatment planning comparison study.
    Radiat Oncol, 4: 34. [Abstract] [Full-text]
  116. Lysyl oxidase propeptide inhibits prostate cancer cell growth by mechanisms that target FGF-2-cell binding and signaling.
    Oncogene, 28(38): 3390-400. [Abstract] [Full-text]
  117. MicroRNA-330 acts as tumor suppressor and induces apoptosis of prostate cancer cells through E2F1-mediated suppression of Akt phosphorylation.
    Oncogene, 28(38): 3360-70. [Abstract] [Full-text]
  118. A luminal epithelial stem cell that is a cell of origin for prostate cancer.
    Nature, 461(7263): 495-500. [Abstract] [Full-text]
  119. Polymorphisms of pro-inflammatory genes and prostate cancer risk: a pharmacogenomic approach.
    Cancer Immunol Immunother, 58(12): 1919-33. [Abstract] [Full-text]
  120. Mre11 inhibition by oncolytic adenovirus associates with autophagy and underlies synergy with ionizing radiation.
    Int J Cancer, 125(10): 2441-9. [Abstract] [Full-text]
  121. Androgen receptor as a potential sign of prostate cancer metastasis.
    Prostate, 69(15): 1704-11. [Abstract] [Full-text]
  122. Genistein and resveratrol, alone and in combination, suppress prostate cancer in SV-40 tag rats.
    Prostate, 69(15): 1668-82. [Abstract] [Full-text]
  123. Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+.
    Prostate, 69(15): 1694-703. [Abstract] [Full-text]
  124. The lily-of-the-valley fragrance receptor--potential in prostate cancer imaging.
    Prostate, 69(15): 1599-602. [Abstract] [Full-text]
  125. In vitro propagation and characterization of neoplastic stem/progenitor-like cells from human prostate cancer tissue.
    Prostate, 69(15): 1683-93. [Abstract] [Full-text]
  126. Comparison of ACINUS, caspase-3, and TUNEL as apoptotic markers in determination of tumor growth rates of clinically localized prostate cancer using image analysis.
    Prostate, 69(15): 1603-10. [Abstract] [Full-text]
  127. A novel androgen-dependent prostate cancer xenograft model derived from skin metastasis of a Japanese patient.
    Prostate, 69(15): 1660-7. [Abstract] [Full-text]
  128. Correlation between selenium concentrations and glutathione peroxidase activity in serum and human prostate tissue.
    Prostate, 69(15): 1635-42. [Abstract] [Full-text]
  129. Clinical and biological significance of CXCR5 expressed by prostate cancer specimens and cell lines.
    Int J Cancer, 125(10): 2288-95. [Abstract] [Full-text]
  130. Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: a randomized, open-label, parallel-group pilot study.
    Prostate, 69(15): 1624-34. [Abstract] [Full-text]
  131. A novel model of bone-metastatic prostate cancer in immunocompetent mice.
    Prostate, 69(15): 1613-23. [Abstract] [Full-text]
  132. Suppression of ErbB-2 in androgen-independent human prostate cancer cells enhances cytotoxic effect by gemcitabine in an androgen-reduced environment.
    Cancer Lett, 285(1): 58-65. [Abstract] [Full-text]
  133. Prostate cancer screening decisions: results from the National Survey of Medical Decisions (DECISIONS study).
    Arch Intern Med, 169(17): 1611-8. [Abstract] [Full-text]
  134. A model of prostate-specific antigen screening outcomes for low- to high-risk men: information to support informed choices.
    Arch Intern Med, 169(17): 1603-10. [Abstract] [Full-text]
  135. Identification of a new prostate cancer susceptibility locus on chromosome 8q24.
    Nat Genet, 41(10): 1055-7. [Abstract] [Full-text]
  136. Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility.
    Nat Genet, 41(10): 1122-6. [Abstract] [Full-text]
  137. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study.
    Nat Genet, 41(10): 1116-21. [Abstract] [Full-text]
  138. Multiple loci on 8q24 associated with prostate cancer susceptibility.
    Nat Genet, 41(10): 1058-60. [Abstract] [Full-text]
  139. A comparative study of recombinant and native frutalin binding to human prostate tissues.
    BMC Biotechnol, 9: 78. [Abstract] [Full-text]
  140. Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement.
    Br J Cancer, 101(7): 1137-44. [Abstract] [Full-text]
  141. Peripheral zone prostate cancer in patients with elevated PSA levels and low free-to-total PSA ratio: detection with MR imaging and MR spectroscopy.
    Radiology, 253(1): 135-43. [Abstract] [Full-text]
  142. Treatment of prostate cancer in unfit senior adult patients.
    Cancer Treat Rev, 35(6): 522-7. [Abstract] [Full-text]
Place a permanent text-link or advertisement here.

© 2004-2013 Prostate Cancer Research Today. All Rights Reserved.



Prostate Cancer Research Today Archive:

Volume 1 (2004)
  Issue 1 (August)
  Issue 2 (September)
  Issue 3 (October)
  Issue 4 (November)
  Issue 5 (December)

Volume 2 (2005)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 3 (2006)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 4 (2007)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 5 (2008)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 6 (2009)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 7 (2010)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 8 (2011)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 9 (2012)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 10 (2013)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)



Prostate Cancer Books

The Prostate Cancer Treatment Book

The Prostate Cancer Treatment Book